Kymera Therapeutics
KYMR
129 hedge funds and large institutions have $1.34B invested in Kymera Therapeutics in 2023 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 49 increasing their positions, 32 reducing their positions, and 17 closing their positions.
320% more call options, than puts
Call options by funds: $1.86M | Put options by funds: $443K
53% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 32
12% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 17
2.57% more ownership
Funds ownership: 103.05% → 105.62% (+2.6%)
2% more funds holding
Funds holding: 127 → 129 (+2)
20% less capital invested
Capital invested by funds: $1.68B → $1.34B (-$340M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$42.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$15.2M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$9.76M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$8M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$7.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$24.1M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$23.6M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$15.5M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$10.2M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$4.56M |
KYMR Hedge Fund Activity: Q2 2023 in Review
129 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q2 2023, worth a combined $1.34B — down 20% from $1.68B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new KYMR positions and 17 closed out — a net gain of 2 holders — while 49 added to existing stakes and 32 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $42.9M. The largest seller was Bank of New York Mellon, cutting an estimated $24.1M.
- 129 institutional investors held Kymera Therapeutics (KYMR) as of Q2 2023, up from 127 in Q1 2023.
- Funds reported $1.34B of Kymera Therapeutics stock for Q2 2023, down 20% quarter-over-quarter.
- 19 funds opened new Kymera Therapeutics positions in Q2 2023 and 17 closed out, a net change of +2 holders.
- The largest Kymera Therapeutics buyer in Q2 2023 was Baker Bros. Advisors, an estimated $42.9M added.
- The largest Kymera Therapeutics seller in Q2 2023 was Bank of New York Mellon, an estimated $24.1M sold.
Based on aggregated 13F filings for Q2 2023.